anticancer/necrosis

Lyen an sove nan clipboard la

Chwazi kalite sòt

Paj 1 soti nan 15075 rezilta yo

Maintenance of cytomegalovirus-specific CD4pos T-cell response in rheumatoid arthritis patients receiving anti-tumor necrosis factor treatments.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

BACKGROUND Anti-tumor necrosis factor (TNF)-α biotherapies have considerably changed the treatment of rheumatoid arthritis (RA). However, serious infections are a major concern in patients with rheumatic diseases treated with anti-TNF-α. Little is known about viral, especially latent, infections in

Disease Status and Pubertal Stage Predict Improved Growth in Antitumor Necrosis Factor Therapy for Pediatric Inflammatory Bowel Disease.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Growth failure is well-recognized in pediatric inflammatory bowel disease (PIBD; <18 years). We aimed to examine whether antitumor necrosis factor (TNF) therapy improves growth in a PIBD population-based cohort. A retrospective review of all Scottish children receiving anti-TNF (infliximab [IFX] and

Tolerance and effectiveness of anti-tumor necrosis factor alpha therapies in elderly patients with rheumatoid arthritis: a population-based cohort study.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

OBJECTIVE Limited data have been published on tolerance to and efficacy of classic or biologic disease-modifying antirheumatic drugs in elderly patients with rheumatoid arthritis (RA). The goal of the present study was to evaluate the tolerance to and effectiveness of anti-tumor necrosis factor

Randomized, placebo-controlled trial of the anti-tumor necrosis factor antibody fragment afelimomab in hyperinflammatory response during severe sepsis: The RAMSES Study.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

OBJECTIVE This study investigated whether treatment with the anti-tumor necrosis factor-alpha monoclonal antibody afelimomab would improve survival in septic patients with serum interleukin (IL)-6 concentrations of >1000 pg/mL. METHODS Multicenter, double-blind, randomized, placebo-controlled

Investigation of rheumatoid arthritis susceptibility genes identifies association of AFF3 and CD226 variants with response to anti-tumour necrosis factor treatment.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

BACKGROUND Anti-tumour necrosis factor (anti-TNF) therapy has proved to be highly successful in treating rheumatoid arthritis (RA), although 30-40% of patients have little or no response. The authors hypothesise that this may be genetically determined. In other complex diseases, susceptibility genes

Magnetic resonance enterography findings as predictors of clinical outcome following antitumor necrosis factor treatment in small bowel Crohn's disease.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

OBJECTIVE To determine whether specific magnetic resonance enterography (MRE) findings can predict outcome following commencement of antitumor necrosis factor (aTNF) in small bowel Crohn's disease (CD) PATIENTS AND METHODS: This was a single-centre retrospective study of patients with CD who

The real-world use of different anti-tumor necrosis factor agents in a Northern European population of patients with Behçet's disease.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

UNASSIGNED The aim of this study was to evaluate prescription practices, treatment responses, and serious adverse events of anti-tumor necrosis factor (anti-TNF) therapies in Behçet's disease (BD). UNASSIGNED Patients with BD satisfying the International Study Group for Behçet's Disease or the

Tumor suppression after tumor cell-targeted tumor necrosis factor alpha gene transfer.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

The tumor necrosis factor alpha (TNF-alpha) gene was introduced by retroviral gene transfer into the TNF-alpha-insensitive tumor cell line J558L. Production of 40 pg/ml TNF-alpha by clone J2T12 consistently did not change the growth rate in vitro, but drastically suppressed tumor growth when

Anti-tumor necrosis factor alpha therapy in fifteen patients with AA amyloidosis secondary to inflammatory arthritides: a followup report of tolerability and efficacy.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

OBJECTIVE Because anti-tumor necrosis factor alpha (anti-TNF) has emerged as a highly effective treatment for numerous inflammatory arthritides, which are a common cause of AA amyloidosis, we retrospectively evaluated the safety and efficacy of anti-TNF in a nationwide study. METHODS The

Influence of variants of Fc gamma receptors IIA and IIIA on the American College of Rheumatology and European League Against Rheumatism responses to anti-tumour necrosis factor alpha therapy in rheumatoid arthritis.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

OBJECTIVE Fc gamma receptor (Fc gammaR) polymorphism influences the affinity of the receptor for Ig, which may, in turn, affect the efficacy of Ig-based therapies. The relationship between functional single nucleotide polymorphisms (SNP) of the FCGR2A and FCGR3A genes and the response to anti-tumour

Ultrasound Elasticity Imaging predicts therapeutic outcomes of patients with Crohn's disease treated with anti-tumor necrosis factor antibodies.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

UNASSIGNED Ultrasound elasticity imaging is a non-invasive technique developed to evaluate fibrosis. Measuring tissue strain by ultrasound elasticity imaging can reliably detect severe ileal fibrosis in patients with Crohn's disease [CD]. We have hypothesised that a more severe range of fibrosis

Interferon-γ release assay versus tuberculin skin test prior to treatment with golimumab, a human anti-tumor necrosis factor antibody, in patients with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

OBJECTIVE To evaluate the performance of an interferon-γ release assay (IGRA) versus the standard tuberculin skin test (TST) as a screening tool for latent tuberculosis (TB) infection prior to the initiation of anti-tumor necrosis factor therapy in patients with autoimmune inflammatory

Effects of anti-tumor necrosis factor agents for familial mediterranean fever patients with chronic arthritis and/or sacroiliitis who were resistant to colchicine treatment.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

BACKGROUND Effectiveness of anti-tumor necrosis factor (anti-TNF) agents in colchicine-resistant familial Mediterranean fever (FMF) patients has attracted attention in recent years. OBJECTIVE We analyzed the effect of anti-TNF agents on clinical findings of colchicine-resistant FMF patients with

Periodontal condition of patients with autoimmune diseases and the effect of anti-tumor necrosis factor-α therapy.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

BACKGROUND The aim of this study is to evaluate the effect of autoimmune diseases (AIs), as well as anti-tumor necrosis factor-α (TNF-α) therapy on the clinical and immunologic parameters of the periodontium. METHODS Thirty-six AI patients (12 rheumatoid arthritis [RA], 12 psoriatic arthritis, and

Anti-tumor necrosis factor-alpha therapy and periodontal parameters in patients with rheumatoid arthritis.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

BACKGROUND The aim of this study was to evaluate the influence of anti-tumor necrosis factor-alpha (TNF-alpha) therapy on the clinical and immunologic parameters of the periodontium. METHODS Ten patients with rheumatoid arthritis (RA) who routinely received infusions of infliximab, 200 mg (RA+), 10

Previous
1
2
3
4
5
6
...
1004
1005
Next

Antre nan paj
facebook nou an

Herbal & Natural Medicine

Baz done ki pi konplè remèd fèy medsin te apiye nan syans

Travay nan 55 lang
Geri èrbal te apiye nan syans
Remèd fèy rekonesans pa imaj
Kat entèaktif GPS - tag zèb sou kote (vini byento)
Li piblikasyon syantifik ki gen rapò ak rechèch ou an
Search remèd fèy medsin pa efè yo
Izeganize enterè ou yo ak rete kanpe fè dat ak rechèch la nouvèl, esè klinik ak rive

Tape yon sentòm oswa yon maladi epi li sou remèd fèy ki ta ka ede, tape yon zèb ak wè maladi ak sentòm li itilize kont.
* Tout enfòmasyon baze sou rechèch syantifik pibliye